{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:22:24Z","timestamp":1794576144475,"version":"4.9.1"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018005","name":"Universidad CES","doi-asserted-by":"publisher","award":["INV.032024.001"],"award-info":[{"award-number":["INV.032024.001"]}],"id":[{"id":"10.13039\/100018005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.curtheres.2026.100834","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:52:14Z","timestamp":1779432734000},"page":"100834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-8552","authenticated-orcid":false,"given":"Sandra Carolina","family":"Dur\u00e1n-Cristiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-3036","authenticated-orcid":false,"given":"Juan David","family":"Ospina-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-0159","authenticated-orcid":false,"given":"Marlies","family":"Gijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5\u20136","key":"10.1016\/j.curtheres.2026.100834_bib0001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00239-015-9705-9","article-title":"SELEX: how it happened and where it will go","volume":"81","author":"Gold","year":"2015","journal-title":"J Mol Evol"},{"key":"10.1016\/j.curtheres.2026.100834_bib0002","article-title":"Recent advances in aptamer discovery, modification and improving performance","volume":"40","author":"Fallah","year":"2024","journal-title":"Biochem Biophys Rep"},{"issue":"12","key":"10.1016\/j.curtheres.2026.100834_bib0003","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00109-013-1085-2","article-title":"Aptamers: multifunctional molecules for biomedical research","volume":"91","author":"Banerjee","year":"2013","journal-title":"J Mol Med (Berl)"},{"issue":"18","key":"10.1016\/j.curtheres.2026.100834_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26188794","article-title":"Monoclonal antibodies: historical perspective and current trends in biological drug development","volume":"26","author":"Madej","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.curtheres.2026.100834_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25136833","article-title":"New insights into aptamers: an alternative to antibodies in the detection of molecular biomarkers","volume":"25","author":"Domsicova","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0006","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2085535","article-title":"Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies","volume":"14","author":"Rafidi","year":"2022","journal-title":"MAbs"},{"issue":"4968","key":"10.1016\/j.curtheres.2026.100834_bib0007","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"issue":"6287","key":"10.1016\/j.curtheres.2026.100834_bib0008","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100834_bib0009","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1021\/acsbiomaterials.5c00504","article-title":"Enhanced glioblastoma-targeted aptamer discovery by 3D cell-SELEX with hyaluronic acid hydrogel","volume":"11","author":"Kim","year":"2025","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.curtheres.2026.100834_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115646","article-title":"From cell-SELEX to tissue-SELEX for targeted drug delivery and aptamer nanomedicine","volume":"224","author":"Wong","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"issue":"22","key":"10.1016\/j.curtheres.2026.100834_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228774","article-title":"Implementation of high-throughput sequencing (HTS) in aptamer selection technology","volume":"21","author":"Komarova","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"44","key":"10.1016\/j.curtheres.2026.100834_bib0012","doi-asserted-by":"crossref","first-page":"17720","DOI":"10.1021\/acs.analchem.4c03972","article-title":"Determining the precision of high-throughput sequencing and its influence on aptamer selection","volume":"96","author":"Canoura","year":"2024","journal-title":"Anal Chem"},{"issue":"20","key":"10.1016\/j.curtheres.2026.100834_bib0013","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1021\/acs.jafc.2c01591","article-title":"Bio-layer interferometry-based SELEX and label-free detection of patulin using generated aptamer","volume":"70","author":"Mukherjee","year":"2022","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.curtheres.2026.100834_bib0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2018.11.007","article-title":"Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics","volume":"14","author":"Le","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100834_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061321","article-title":"Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction","volume":"18","author":"Achari","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100834_bib0016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12195-020-00664-7","article-title":"Engineered aptamers for enhanced COVID-19 theranostics","volume":"14","author":"Acquah","year":"2021","journal-title":"Cell Mol Bioeng"},{"key":"10.1016\/j.curtheres.2026.100834_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2018.07.009","article-title":"Succinate induces synovial angiogenesis in rheumatoid arthritis through metabolic remodeling and HIF-1\u03b1\/VEGF axis","volume":"126","author":"Li","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.curtheres.2026.100834_bib0018","first-page":"1","article-title":"Aptamer-directed siRNA delivery systems for triple-negative breast cancer therapy","volume":"26","author":"Singh","year":"2025","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100834_bib0019","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100834_bib0020","article-title":"Age-related macular degeneration: an exponentially emerging imminent threat of visual impairment and irreversible blindness","volume":"15","author":"Chaudhuri","year":"2023","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.curtheres.2026.100834_bib0021","first-page":"7","article-title":"Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment","volume":"14","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.curtheres.2026.100834_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40942-025-00779-x","article-title":"Histopathologic evidence of VEGF in early neovascular AMD: from a 1992 hypothesis to a 1994 discovery\u2014a historical perspective","volume":"11","author":"Dastgheib","year":"2025","journal-title":"Int J Retina Vitreous"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100834_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ph16081140","article-title":"Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders","volume":"16","author":"Hang","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.curtheres.2026.100834_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF is required for visual function: evidence for a survival role on M\u00fcller cells and photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.curtheres.2026.100834_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/319728","article-title":"Antivascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"2012","author":"Zampros","year":"2012","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.curtheres.2026.100834_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17030394","article-title":"The 20th anniversary of pegaptanib (MacugenTM), the first approved aptamer medicine: history, recent advances and future prospects of aptamers in therapy","volume":"17","author":"Bege","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate","volume":"114","author":"Adamis","year":"1996","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"issue":"27","key":"10.1016\/j.curtheres.2026.100834_bib0028","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0029","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"10.1016\/j.curtheres.2026.100834_bib0030","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1093\/nar\/gkz589","article-title":"Insights into the G-rich VEGF-binding aptamer V7t1: when two G-quadruplexes are better than one!","volume":"47","author":"Moccia","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0031","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12886-019-1228-5","article-title":"Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100834_bib0032","first-page":"4022","article-title":"Platelet-derived growth factor-BB promotes proliferation and migration of retinal microvascular pericytes by up-regulating the expression of C-X-C chemokine receptor types 4","volume":"18","author":"Xiang","year":"2019","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0033","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ophtha.2015.09.004","article-title":"A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration","volume":"123","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.curtheres.2026.100834_bib0034","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.omtn.2019.07.018","article-title":"Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease","volume":"17","author":"Matsuda","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100834_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071617","article-title":"Multiple therapeutic applications of RBM-007, an anti-FGF2 aptamer","volume":"10","author":"Nakamura","year":"2021","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100834_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083463","article-title":"Role of oxidative stress and inflammation in age related macular degeneration: insights into the retinal pigment epithelium (RPE)","volume":"26","author":"Ochoa Hern\u00e1ndez","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100834_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070763","article-title":"Interlink between inflammation and oxidative stress in age-related macular degeneration: role of complement factor H","volume":"9","author":"Romero-Vazquez","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100834_bib0038","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/nat.2019.0833","article-title":"Anti-CD44 DNA aptamers selectively target cancer cells","volume":"30","author":"P\u0119cak","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.curtheres.2026.100834_bib0039","article-title":"CD44 aptamer mediated cargo delivery to lysosomes of retinal pigment epithelial cells to prevent age-related macular degeneration","volume":"18","author":"Chandola","year":"2019","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.curtheres.2026.100834_bib0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2147\/OPTH.S518398","article-title":"Real-world outcomes with complement inhibitors for geographic atrophy: a comparative study of pegacetacoplan versus avacincaptad pegol","volume":"19","author":"Rush","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.curtheres.2026.100834_bib0041","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/aam.aam_186_23","article-title":"Izervay versus Syfovre: two rivals recently approved for management of geographic atrophy","volume":"23","author":"Patel","year":"2024","journal-title":"Ann Afr Med"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2024-001854","article-title":"New horizons in geographic atrophy treatment: enthusiasm and caution surrounding complement inhibitors","volume":"9","author":"Lai","year":"2024","journal-title":"BMJ Open Ophthalmol"},{"issue":"23","key":"10.1016\/j.curtheres.2026.100834_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313150","article-title":"AS1411 nucleolin-specific binding aptamers reduce pathological angiogenesis through inhibition of nucleolin phosphorylation","volume":"22","author":"Iturriaga-Goyon","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0044","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2214-109X(20)30425-3","article-title":"Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study","volume":"9","author":"Bourne","year":"2021","journal-title":"Lancet Glob Heal"},{"issue":"12","key":"10.1016\/j.curtheres.2026.100834_bib0045","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Heal"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100834_bib0046","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/1566524022666220508182051","article-title":"Glaucoma: biological mechanism and its clinical translation","volume":"23","author":"Dur\u00e1n-Cristiano","year":"2022","journal-title":"Curr Mol Med"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0047","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4103\/ijo.IJO_1158_21","article-title":"Neuroprotection in glaucoma","volume":"70","author":"Vishwaraj","year":"2022","journal-title":"Indian J Ophthalmol"},{"issue":"30","key":"10.1016\/j.curtheres.2026.100834_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202500623","article-title":"High-efficiency ocular delivery of brain-derived neurotrophic factor and oligomycin for neuroprotection in glaucoma","volume":"37","author":"Cao","year":"2025","journal-title":"Adv Mater"},{"issue":"18","key":"10.1016\/j.curtheres.2026.100834_bib0049","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1039\/D2LC00431C","article-title":"Quantitative brain-derived neurotrophic factor lateral flow assay for point-of-care detection of glaucoma","volume":"22","author":"Wu","year":"2022","journal-title":"Lab Chip"},{"issue":"17","key":"10.1016\/j.curtheres.2026.100834_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176262","article-title":"Neuroprotection of retinal ganglion cells with AAV2-BDNF pretreatment restoring normal TrkB receptor protein levels in glaucoma","volume":"21","author":"W\u00f3jcik-Gryciuk","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.curtheres.2026.100834_bib0051","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/IJG.0000000000002257","article-title":"Reduced plasma BDNF levels in normal tension glaucoma compared to open angle glaucoma","volume":"32","author":"Sato","year":"2023","journal-title":"J Glaucoma"},{"key":"10.1016\/j.curtheres.2026.100834_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.121997","article-title":"A novel biosensing platform for detection of glaucoma biomarker GDF15 via an integrated BLI-ELASA strategy","volume":"294","author":"Gao","year":"2023","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100834_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031009","article-title":"Fibrosis and Src signalling in glaucoma: from molecular pathways to therapeutic prospects","volume":"26","author":"Bourke","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.curtheres.2026.100834_bib0054","first-page":"2151","article-title":"sCD44 overexpression increases intraocular pressure and aqueous outflow resistance","volume":"19","author":"Giovingo","year":"2013","journal-title":"Mol Vis"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100834_bib0055","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1167\/iovs.14-14578","article-title":"Elevated transforming growth factor \u03b21 in plasma of primary open-angle glaucoma patients","volume":"55","author":"Kuchtey","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.curtheres.2026.100834_bib0056","doi-asserted-by":"crossref","first-page":"8837","DOI":"10.18632\/aging.102997","article-title":"The T\u03b2R II-targeted aptamer S58 prevents fibrosis after glaucoma filtration surgery","volume":"12","author":"Li","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0057","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/acschemneuro.3c00661","article-title":"Isolation and identification of the high-affinity DNA aptamer target to the brain-derived neurotrophic factor (BDNF)","volume":"15","author":"Chowdhury","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100834_bib0058","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1021\/acsami.0c18626","article-title":"Improved treatment options for glaucoma with brimonidine-loaded lipid DNA nanoparticles","volume":"13","author":"Schnichels","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"issue":"10","key":"10.1016\/j.curtheres.2026.100834_bib0059","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1039\/D4SD00223G","article-title":"Selection of DNA aptamers for sensing drugs treating eye disease: atropine and timolol maleate\u2020\u2021 \u2020The authors have filed patent related to this work. \u2021Electronic supplementary information (ESI) available. See","volume":"3","author":"Wong","year":"2024","journal-title":"Sens Diagn"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100834_bib0060","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41433-020-01339-3","article-title":"Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance","volume":"35","author":"Ting","year":"2021","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0061","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ceo.13672","article-title":"Antimicrobial resistance trends in bacterial keratitis over 5\u2009years in Sydney, Australia","volume":"48","author":"Cabrera-Aguas","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"issue":"21","key":"10.1016\/j.curtheres.2026.100834_bib0062","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111682","article-title":"A novel methylene blue indicator-based aptasensor for rapid detection of Pseudomonas aeruginosa","volume":"25","author":"Maghsoomi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"47","key":"10.1016\/j.curtheres.2026.100834_bib0063","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304194","article-title":"DNA nanoflower eye drops with antibiotic-resistant gene regulation ability for MRSA keratitis target treatment","volume":"19","author":"Ran","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.curtheres.2026.100834_bib0064","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.omtn.2017.10.009","article-title":"Targeting Herpes simplex virus-1 gD by a DNA aptamer can be an effective new strategy to curb viral infection","volume":"9","author":"Yadavalli","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.curtheres.2026.100834_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.107977","article-title":"Corneal neovascularization is inhibited with nucleolin-binding aptamer, AS1411","volume":"193","author":"Vivanco-Rojas","year":"2020","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100834_bib0066","doi-asserted-by":"crossref","DOI":"10.3390\/ph16050751","article-title":"Assessment of aptamer as a potential drug targeted delivery for retinal angiogenesis inhibition","volume":"16","author":"Moreira","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10.1016\/j.curtheres.2026.100834_bib0067","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1073\/pnas.0831159100","article-title":"Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2","volume":"100","author":"White","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0068","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060531","article-title":"Patterns in the development of pediatric allergy","volume":"152","author":"Gabryszewski","year":"2023","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0069","first-page":"134","article-title":"Association between keratoconus and allergic conjunctivitis in children attending a Tertiary Hospital in Nigeria","volume":"67","author":"Balogun","year":"2023","journal-title":"Rom J Ophthalmol"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4274\/tjo.galenos.2020.11456","article-title":"Current knowledge in allergic conjunctivitis","volume":"51","author":"Villegas","year":"2021","journal-title":"Turkish J Ophthalmol"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100834_bib0071","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaip.2019.10.011","article-title":"Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis","volume":"8","author":"Fukuda","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100834_bib0072","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/ajd.13924","article-title":"Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting","volume":"63","author":"Foley","year":"2022","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100834_bib0073","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100834_bib0074","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/ac0483926","article-title":"DNA aptamer-based bioanalysis of IgE by fluorescence anisotropy","volume":"77","author":"Gokulrangan","year":"2005","journal-title":"Anal Chem"},{"key":"10.1016\/j.curtheres.2026.100834_bib0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1039\/D5NR04649A","article-title":"Cornea-SELEX-derived DNA aptamers for preparing spherical nucleic acids and corneal staining","volume":"18","author":"Zhang","year":"2026","journal-title":"Nanoscale"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100834_bib0076","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/1074-5521(95)90188-4","article-title":"A novel RNA motif for neomycin recognition","volume":"2","author":"Wallis","year":"1995","journal-title":"Chem Biol"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0077","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ab.2011.04.007","article-title":"Gold nanoparticle-based colorimetric detection of kanamycin using a DNA aptamer","volume":"415","author":"Song","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1016\/j.curtheres.2026.100834_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2026.118569","article-title":"High affinity and selective DNA aptamers for the detection of tobramycin in eye drops","volume":"303","author":"Zhang","year":"2026","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.curtheres.2026.100834_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.01.057","article-title":"Advances and limitations of drug delivery systems formulated as eye drops","volume":"321","author":"Jumelle","year":"2020","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100834_bib0080","article-title":"Cornea-SELEX for aptamers targeting the surface of eyes and liposomal drug delivery","volume":"4","author":"Wong","year":"2024","journal-title":"Explor (Beijing, China)"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0081","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular drug delivery: a comprehensive review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.curtheres.2026.100834_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.114639","article-title":"Highly sensitive protein detection by aptamer-based single-molecule kinetic fingerprinting","volume":"216","author":"Chatterjee","year":"2022","journal-title":"Biosens Bioelectron"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100834_bib0083","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202401572","article-title":"Dissociation constant (K(d)) measurement for small-molecule binding aptamers: homogeneous assay methods and critical evaluations","volume":"9","author":"Stangherlin","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.curtheres.2026.100834_bib0084","article-title":"The screening of aptamers and the development of a colorimetric detection method for the pesticide deltamethrin","volume":"25","author":"Wu","year":"2025","journal-title":"Sensors"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0085","doi-asserted-by":"crossref","first-page":"bpaf046","DOI":"10.1093\/biomethods\/bpaf046","article-title":"Advances and future directions of aptamer-functionalized nanoparticles for point-of-care diseases diagnosis","volume":"10","author":"Fasogbon","year":"2025","journal-title":"Biol Methods Protoc"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100834_bib0086","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073102","article-title":"The art of PEGylation: from simple polymer to sophisticated drug delivery system","volume":"26","author":"Makharadze","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.curtheres.2026.100834_bib0087","unstructured":"ClinicalTrials.gov. A Phase 3 Safety and Efficacy Study of Fovista\u00ae (E10030) Intravitreous Administration in Combination With Lucentis\u00ae Compared to Lucentis\u00ae Monotherapy. Identifier: NCT01944839. Bethesda (MD): National Library of Medicine (US). Available from: ClinicalTrials.gov. Accessed June 05, 2026."},{"issue":"21","key":"10.1016\/j.curtheres.2026.100834_bib0088","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115926","article-title":"The effect of anti-autotaxin aptamers on the development of proliferative vitreoretinopathy","volume":"24","author":"Hanazaki","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10411","key":"10.1016\/j.curtheres.2026.100834_bib0089","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100834_bib0090","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ophtha.2025.12.011","article-title":"Avacincaptad Pegol for geographic atrophy secondary to age-related macular degeneration: two-year efficacy and safety results from the GATHER2 phase 3 trial","volume":"133","author":"Khanani","year":"2026","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0091","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2025-002232","article-title":"Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-na\u00efve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study","volume":"11","author":"Patel","year":"2026","journal-title":"BMJ Open Ophthalmol"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100834_bib0092","article-title":"Advances in the mechanism and therapies of achondroplasia","volume":"12","author":"Chen","year":"2025","journal-title":"Genes Dis"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100834_bib0093","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf219","article-title":"Exploring the relationship between aptamer binding thermodynamics, affinity, and specificity","volume":"53","author":"Alkhamis","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100834_bib0094","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21061963","article-title":"Tuning the polymorphism of the anti-VEGF G-rich V7t1 aptamer by covalent dimeric constructs","volume":"21","author":"Riccardi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.curtheres.2026.100834_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117027","article-title":"Development of hybrid aptamers-engineered PROTACs for degrading VEGF165 in both tumor- and vascular endothelial cells","volume":"281","author":"Feng","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100834_bib0096","doi-asserted-by":"crossref","first-page":"690","DOI":"10.18240\/ijo.2022.05.02","article-title":"Exosome-mediated aptamer S58 reduces fibrosis in a rat glaucoma filtration surgery model","volume":"15","author":"Lin","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.curtheres.2026.100834_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108338","article-title":"Treatment with GDF15, a TGF\u03b2 superfamily protein, induces protective effect on retinal ganglion cells","volume":"202","author":"Iwata","year":"2021","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100834_bib0098","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030744","article-title":"Elevated levels of growth\/differentiation factor-15 in the aqueous humor and serum of Glaucoma patients","volume":"11","author":"Maddala","year":"2022","journal-title":"J Clin Med"},{"issue":"18","key":"10.1016\/j.curtheres.2026.100834_bib0099","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26189109","article-title":"Exploring molecular and clinical dimensions of glaucoma as a neurodegenerative disease","volume":"26","author":"Dur\u00e1n-Cristiano","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.curtheres.2026.100834_bib0100","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1021\/acs.langmuir.1c00166","article-title":"Nuclease hydrolysis does not drive the rapid signaling decay of DNA aptamer-based electrochemical sensors in biological fluids","volume":"37","author":"Shaver","year":"2021","journal-title":"Langmuir"},{"issue":"10","key":"10.1016\/j.curtheres.2026.100834_bib0101","article-title":"Polyethylene glycol (PEG)-induced anaphylaxis: a cautionary case for the gastroenterologist in the COVID era","volume":"17","author":"Fazel Darbandi","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0102","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2494775","article-title":"PEGylation technology: addressing concerns, moving forward","volume":"32","author":"Simberg","year":"2025","journal-title":"Drug Deliv"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100834_bib0103","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.survophthal.2026.02.005","article-title":"Ocular inflammation after intraocular drug delivery: mechanisms, risk factors, and implications for clinical practice","volume":"71","author":"Ferro Desideri","year":"2026","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12951-019-0498-7","article-title":"Liposomes for effective drug delivery to the ocular posterior chamber","volume":"17","author":"Lai","year":"2019","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100834_bib0105","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1093\/nar\/gkt128","article-title":"Single-molecule chemical denaturation of riboswitches","volume":"41","author":"Dalgarno","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100834_bib0106","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17030375","article-title":"Revolutionizing drug delivery: the impact of advanced materials science and technology on precision medicine","volume":"17","author":"El-Tanani","year":"2025","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100834_bib0107","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1021\/acsabm.3c01075","article-title":"Electrochemical nanoaptasensor based on graphitic carbon nitride\/zirconium dioxide\/multiwalled carbon nanotubes for matrix metalloproteinase-9 in Human serum and saliva","volume":"7","author":"Ansari","year":"2024","journal-title":"ACS Appl bio Mater"},{"key":"10.1016\/j.curtheres.2026.100834_bib0108","article-title":"Electrochemical aptasensor for ultrasensitive detection of glycated hemoglobin (HbA1c) using gold-modified SPCE","volume":"47","author":"Zuliska","year":"2025","journal-title":"Sens Bio-Sens Res"},{"issue":"19","key":"10.1016\/j.curtheres.2026.100834_bib0109","article-title":"Nano-phase separation and analyte binding in aptasensors investigated by nano-IR spectroscopy","volume":"21","author":"Samiseresht","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.curtheres.2026.100834_bib0110","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/861904","article-title":"Ophthalmic drug dosage forms: characterisation and research methods","volume":"2014","author":"Baranowski","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.curtheres.2026.100834_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116437","article-title":"An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma","volume":"174","author":"Wang","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100834_bib0112","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17050599","article-title":"Ocular drug delivery: emerging approaches and advances","volume":"17","author":"Gade","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100834_bib0113","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41433-019-0665-y","article-title":"Eye drop technique and patient-reported problems in a real-world population of eye drop users","volume":"34","author":"Mehuys","year":"2020","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0114","doi-asserted-by":"crossref","DOI":"10.1177\/11206721221144339","article-title":"Ocular surface disease signs and symptoms of glaucoma patients and their relation to glaucoma medication in Finland","volume":"33","author":"Parkkari","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100834_bib0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/biom14010030","article-title":"Comparison of transcriptomic analysis of the conjunctiva in glaucoma-treated eyes with dry eyes and healthy controls","volume":"14","author":"Carnero","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.curtheres.2026.100834_bib0116","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.2147\/OPTH.S476779","article-title":"Ocular surface disease and dry eye severity in glaucoma patients at urban private eye care centres in Malaysia","volume":"18","author":"Gan","year":"2024","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100834_bib0117","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives","volume":"11","author":"Gaballa","year":"2021","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100834_bib0118","doi-asserted-by":"crossref","DOI":"10.3390\/s26020433","article-title":"Electrochemical biosensors for exosome detection: current advances, challenges, and prospects for Glaucoma diagnosis","volume":"26","author":"Moreno-Guzm\u00e1n","year":"2026","journal-title":"Sensors (Basel)"},{"issue":"12","key":"10.1016\/j.curtheres.2026.100834_bib0119","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/1750743X.2024.2368342","article-title":"C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review","volume":"16","author":"Danzig","year":"2024","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100834_bib0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/nat.2020.0875","article-title":"Development of Human CBF1-Targeting Single-Stranded DNA Aptamers with Antiangiogenic Activity In Vitro","volume":"30","author":"Tezuka-Kagajo","year":"2020","journal-title":"Nucleic Acid Ther"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:23:35Z","timestamp":1794572615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X26000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":120,"alternative-id":["S0011393X26000159"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100834","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100834"}}